US2021353544A1PendingUtilityA1
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
Est. expirySep 14, 2025(expired)· nominal 20-yr term from priority
A61P 5/50A61P 31/00A61K 38/28A61K 9/1611A61P 5/18A61K 9/167A61K 38/13A61P 31/12A61P 7/02A61P 37/04A61K 38/27A61K 9/48A61K 9/1676A61K 9/1623A61P 3/00A61K 38/26A61K 38/29A61K 9/1617A61P 5/48A61K 9/5089A61P 25/00A61K 38/22A61K 38/25A61P 37/00A61P 35/00A61K 9/5052A61K 9/14A61K 9/0073A61K 31/549A61K 9/16
79
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A pharmaceutical composition comprising microparticles made by a method for making a microparticle coated with an active agent that is of pharmaceutical use, the method comprising:
(i) obtaining a crystalline fumaryl diketopiperazine microparticle wherein the crystalline diketopiperazine microparticle does not comprise an active agent; (ii) forming a suspension comprising said crystalline diketopiperazine microparticle and a solvent; (iii) dissolving said active agent in the fluid phase of said suspension; (iv) increasing the pH of the fluid phase to about 4 to 5 ; (v) adsorbing of said active agent onto a surface of said crystalline fumaryl diketopiperazine microparticle to provide a coating of said active agent on said crystalline fumaryl diketopiperazine microparticle; and (vi) removing or exchanging said solvent after step (v).
2 . A pharmaceutical composition comprising microparticles made by the method of claim 1 .
3 . The pharmaceutical composition of claim 1 , wherein the active agent is a protein, peptide, polypeptide, small molecule, or nucleic acid molecule.
4 . The pharmaceutical composition of claim 1 , wherein the active agent is glucagon-like peptide 1 (GLP-1).
5 . The pharmaceutical composition of claim 1 , wherein the active agent is vasoactive, or anticoagulant.
6 . The pharmaceutical composition of claim 1 , wherein the active agent is a neuroactive agent.
7 . The pharmaceutical composition of claim 1 , wherein the active agent is a hormone.
8 . The pharmaceutical composition of claim 1 , wherein the active agent is an, antibiotic agent, antiviral agent, antigenic agent, immunomodulating agent, cytotoxic agent, or antibody.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.